ALLK Projected Dividend Yield
Allakos Inc ( NASDAQ : ALLK )Allakos is a clinical stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. Co.'s antibodies are lirentelimab (AK002) and AK006. Co. is developing lirentelimab for the treatment of eosinophilic gastritis/eosinophilic duodenitis, eosinophilic esophagitis, atopic dermatitis, chronic spontaneous urticaria and potentially additional indications. AK006 targets Siglec-6, an inhibitory receptor selectively expressed on various cells. AK006 appears to have the potential to provide various cell inhibition than lirentelimab. 20 YEAR PERFORMANCE RESULTS |
ALLK Dividend History Detail ALLK Dividend News ALLK Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |